EBS Insider Trading
Insider Ownership Percentage: 1.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $279,880.72
Emergent BioSolutions Insider Trading History Chart
This chart shows the insider buying and selling history at Emergent BioSolutions by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Emergent BioSolutions Share Price & Price History
Current Price: $5.74
Price Change: ▲ Price Increase of +0.225 (4.08%)
As of 03/14/2025 04:59 PM ET
Emergent BioSolutions Insider Trading History
Emergent BioSolutions Institutional Trading History
Data available starting January 2016
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Read More on Emergent BioSolutions
Volume
990,340 shs
Average Volume
2,629,734 shs
Market Capitalization
$311.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.8
Who are the company insiders with the largest holdings of Emergent BioSolutions?
Who are the major institutional investors of Emergent BioSolutions?
Which institutional investors are selling Emergent BioSolutions stock?
In the last quarter, EBS stock was sold by these institutional investors:
- Marshall Wace LLP
- Charles Schwab Investment Management Inc.
- Whitebox Advisors LLC
- D. E. Shaw & Co. Inc.
- Vanguard Group Inc.
- Susquehanna International Group LLP
- Squarepoint Ops LLC
- Cubist Systematic Strategies LLC
Within the previous year, company insiders that have sold Emergent BioSolutions company stock include:
- Neal Franklin Fowler (Director)
- Kathryn C Zoon (Director)
Learn More investors selling Emergent BioSolutions stock.
Which institutional investors are buying Emergent BioSolutions stock?
In the last quarter, EBS stock was acquired by institutional investors including:
- Millennium Management LLC
- Invesco Ltd.
- Dimensional Fund Advisors LP
- American Century Companies Inc.
- Trexquant Investment LP
- Allspring Global Investments Holdings LLC
- Man Group plc
- Morse Asset Management Inc